Cardiovascular disease: PDE9A inhibition mends broken hearts

Nature Reviews Drug Discovery

Volumn 14, Issue 5, 2015, Pages 310-311

  Bray, Natasha ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; PF 9613; PHOSPHODIESTERASE; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE 9A; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG; CYCLIC AMP PHOSPHODIESTERASE; NITRIC OXIDE;

DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; GENE EXPRESSION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CARDIOMEGALY; ENZYMOLOGY; MALE; METABOLISM;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; CARDIOMEGALY; CYCLIC GMP; HUMANS; MALE; NITRIC OXIDE;

EID: 84929024840     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4618     Document Type: Note

References (1)

1. Lee, D. I. et al. Phosphodiesterase 9A controls nitric-oxideindependent cGMP and hypertrophic heart disease. Nature 519, 472-476 (2015)